NASDAQ · MXCT
MaxCyte, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MXCT: Nov 10, 2026
MaxCyte, Inc. Common Stock is expected to report earnings on 11/10/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Dec 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews · MarketBeat- Zacks · Oct 29, 6:45 AM EDTFortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass EstimatesFortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 6, 4:07 AM EDTEmergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- The Motley Fool · Aug 19, 7:01 PM EDTMaxCyte (MXCT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 19, 8:26 AM EDTMaxCyte Launches New Off-Target Assays For Base Editing Therapies(RTTNews) – MaxCyte, Inc. (MXCT) launched CHANGE-seq-BE and ONE-seq-BE off-target nomination assays through its SeQure service, expanding its genome editing risk assessment capabilities for adenine and cytosine base editors.
- MarketBeat · Aug 12, 9:04 PM EDTMaxCyte Q2 Earnings Call HighlightsMaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purc
- Zacks · Aug 12, 6:15 PM EDTMaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue EstimatesMaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 11, 8:20 AM EDTAdherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue EstimatesAdherex Technologies (FENC) delivered earnings and revenue surprises of +400.00% and +11.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTNuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue EstimatesNuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 8:15 AM EDTKymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue EstimatesKymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 4, 5:40 PM EDTAcadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat EstimatesAcadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 22, 4:01 AM EDTMaxCyte Signs Multi-Platform Technology License Partnership With Genentech(RTTNews) – MaxCyte, Inc. (MXCT) has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group (RHHBY), to advance the development of next-generation cell therapy programs.
- MarketBeat · May 12, 9:09 PM EDTMaxCyte Q1 Earnings Call HighlightsMaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while mi
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for MaxCyte, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.